Equities research analysts expect Halyard Health, Inc. (NYSE:HYH) to report earnings per share of $0.50 for the current quarter, Zacks reports. Four analysts have made estimates for Halyard Health’s earnings, with the highest EPS estimate coming in at $0.51 and the lowest estimate coming in at $0.49. Halyard Health also posted earnings of $0.50 per share during the same quarter last year. The business is expected to report its next quarterly earnings report on Monday, February 26th.

According to Zacks, analysts expect that Halyard Health will report full-year earnings of $2.02 per share for the current year, with EPS estimates ranging from $1.91 to $2.09. For the next financial year, analysts forecast that the firm will report earnings of $2.13 per share, with EPS estimates ranging from $2.00 to $2.27. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Halyard Health.

Halyard Health (NYSE:HYH) last issued its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported $0.60 EPS for the quarter, beating the Zacks’ consensus estimate of $0.47 by $0.13. The firm had revenue of $401.40 million for the quarter, compared to analysts’ expectations of $394.54 million. Halyard Health had a net margin of 3.52% and a return on equity of 8.65%. The firm’s revenue was up 1.0% on a year-over-year basis. During the same period in the prior year, the company earned $0.48 EPS.

A number of brokerages recently commented on HYH. Stifel Nicolaus reissued a “buy” rating and issued a $52.00 price objective on shares of Halyard Health in a research note on Friday. ValuEngine raised shares of Halyard Health from a “hold” rating to a “buy” rating in a research note on Saturday. Zacks Investment Research raised shares of Halyard Health from a “hold” rating to a “buy” rating and set a $44.00 price objective on the stock in a research note on Wednesday, July 12th. Deutsche Bank AG increased their price objective on shares of Halyard Health from $35.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, August 3rd. Finally, Stephens raised shares of Halyard Health from an “equal weight” rating to an “overweight” rating in a research note on Thursday, August 3rd. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Halyard Health has a consensus rating of “Buy” and an average price target of $44.00.

Shares of Halyard Health (NYSE HYH) traded up $0.33 during midday trading on Friday, reaching $47.33. 509,701 shares of the company were exchanged, compared to its average volume of 456,112. The firm has a market cap of $2,216.75, a PE ratio of 22.65, a price-to-earnings-growth ratio of 3.16 and a beta of 1.69. Halyard Health has a 12-month low of $32.60 and a 12-month high of $50.99. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.11 and a current ratio of 2.13.

ILLEGAL ACTIVITY NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.watchlistnews.com/halyard-health-inc-hyh-expected-to-announce-earnings-of-0-50-per-share/1681245.html.

Institutional investors have recently added to or reduced their stakes in the business. Riverhead Capital Management LLC boosted its stake in shares of Halyard Health by 88.1% during the 2nd quarter. Riverhead Capital Management LLC now owns 3,197 shares of the medical instruments supplier’s stock worth $126,000 after purchasing an additional 1,497 shares during the last quarter. LS Investment Advisors LLC boosted its stake in shares of Halyard Health by 16.1% during the 2nd quarter. LS Investment Advisors LLC now owns 4,017 shares of the medical instruments supplier’s stock worth $158,000 after purchasing an additional 556 shares during the last quarter. Victory Capital Management Inc. boosted its stake in shares of Halyard Health by 17.7% during the 2nd quarter. Victory Capital Management Inc. now owns 4,732 shares of the medical instruments supplier’s stock worth $186,000 after purchasing an additional 711 shares during the last quarter. QS Investors LLC boosted its stake in shares of Halyard Health by 305.6% during the 2nd quarter. QS Investors LLC now owns 5,176 shares of the medical instruments supplier’s stock worth $203,000 after purchasing an additional 3,900 shares during the last quarter. Finally, Quotient Investors LLC acquired a new stake in shares of Halyard Health during the 3rd quarter worth about $203,000. 91.03% of the stock is currently owned by institutional investors.

About Halyard Health

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Get a free copy of the Zacks research report on Halyard Health (HYH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.